Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05859217 · ClinicalTrials.gov registry record · Phase 2
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
A Phase 2 study, sponsored by Jun Zhang, MD, PhD.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT05859217 is a Phase 2 study that has not yet begun recruiting, run by Jun Zhang, MD, PhD. The registered enrollment target is 40 participants.
The verdict
NCT05859217, a Phase 2 study, has not yet begun recruiting, sponsored by Jun Zhang, MD, PhD.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab). In this study, investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and atezolizumab will result in better therapeutic value.
Interventions
- DRUG Atezolizumab
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-12 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05859217
The ClinicalTrials.gov registry entry for NCT05859217 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jun Zhang, MD, PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT05859217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05859217 about?
NCT05859217 is a clinical study titled "A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)". NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab). In this study, investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and atezolizumab will result i...
What is the current status of trial NCT05859217?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-12. Estimated completion is 2028-06.
What interventions are being tested in trial NCT05859217?
The interventions under investigation include: Atezolizumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT05859217?
This trial is sponsored by Jun Zhang, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.